Neogen AI Stock Analysis
Want to see NEOG full AI Analyst Report?
Neogen (NEOG) AI Stock Analysis
Neogen
(NASDAQ:NEOG)
NEOG’s score is driven primarily by improving fundamentals signaled in the latest earnings call (raised FY27 guidance and expectations for meaningful cash flow improvement) and a relatively supportive financial base (stronger balance sheet and recent positive free cash flow). These positives are tempered by ongoing net losses and historical earnings volatility, while technical indicators and valuation (negative P/E and no dividend yield provided) remain moderate-to-weak.
Neogen Key Performance Indicators (KPIs)
Revenue by GeographyBreaks down revenue across different regions, revealing where the company is strongest and where it may face risk or growth potential due to local economic conditions or market share shifts.
There’s a clear step-up in the business around late‑2022 that lifted the revenue baseline in both Domestic and International—consistent with portfolio expansion rather than a one‑quarter spike—and since then the two regions have traded places as the primary growth driver. Post‑2022 results look range‑bound and seasonal, so future upside will likely come from execution (pricing, new products, M&A) and stronger international penetration; watch integration, international margin trends, and whether overseas growth sustains beyond occasional quarter-to-quarter beats.
Neogen (NEOG) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $2.38B
- Dividend Yield
- ―
- Average Volume (3M)
- 3.47M
- Price to Earnings (P/E)
- -43.1
- Beta (1Y)
- 0.84
- Revenue Growth
- -0.33%
- EPS Growth
- 94.64%
- Country
- US
- Employees
- 2,636
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Devices
Neogen Business Overview & Revenue Model
Company Description
Neogen Corporation, including its affiliated companies, is a global leader in creating, manufacturing, and distributing a wide range of products crucial for maintaining food quality and animal health. The enterprise is structured into two primary div...
How the Company Makes Money
Neogen primarily makes money by selling products and services that support testing and monitoring in food safety and animal safety workflows. A major portion of revenue is generated from recurring consumables and test kits used in routine screening (...
Neogen Earnings Call Summary
The call was predominantly positive. Neogen reported broad-based revenue growth, improved adjusted EBITDA margins and free cash flow, raised fiscal 2027 guidance, advanced commercial and innovation initiatives, and reached an important Petrifilm validation milestone. Management also highlighted near-term growth timing effects, macroeconomic pressures, transition-related duplicative costs and a full-year EBITDA margin outlook roughly similar to fiscal 2026, but described these issues as understood and incorporated into its plans.
Q1-2027 Updates
Positive Updates
Negative Updates
Company Guidance
For fiscal year 2027, Neogen raised revenue guidance to $885 million to $890 million and adjusted EBITDA guidance to $181 million to $183 million, with the genomics business continuing to be included; the second quarter is expected to see the lowest level of core growth, first-half core growth is expected to be “in the range of approximately 3.5%,” and first-half adjusted EBITDA margin is expected to be “in line with the first quarter,” while full-year EBITDA margins are expected to be “roughly similar” to fiscal year '26. The company expects to expand adjusted EBITDA margins through progress in key operational efficiency programs, and maintains its view that both GAAP cash flow from operations and free cash flow will “increase meaningfully on a year-over-year basis”; the genomics divestiture is expected to receive a final decision by the end of December, with expected net proceeds of approximately $140 million, which would put net leverage below 3x at closing and closer to 2.5x by the end of the fiscal year. The Petrifilm manufacturing transfer is expected to begin the planned multi-quarter transfer next month, and after transitioning over through fiscal year '28, Neogen expects margin improvement of 200 to 300 basis points in FY '29, with improvements beginning in the first fiscal year and fully implemented in the second year.
Neogen Financial Statement Overview
Summary
Balance sheet strength is a key positive (TTM shows zero debt and a large equity base), and cash flow has recently turned positive with improved free cash flow. Offsetting that, profitability is still weak with a net loss and slightly negative EBIT, and multi-year earnings have been volatile (including a very large loss in 2025), which weighs on overall financial quality.
Income Statement
44NeutralBalance Sheet
72PositiveCash Flow
63Positive| Breakdown | TTM | May 2026 | May 2025 | May 2024 | May 2023 | May 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 883.99M | 870.40M | 894.66M | 924.22M | 822.45M | 527.16M |
| Gross Profit | 418.98M | 408.50M | 421.38M | 462.63M | 405.95M | 243.01M |
| EBITDA | 105.13M | 164.90M | -937.75M | 182.60M | 124.39M | 84.34M |
| Net Income | -56.12M | -7.90M | -1.09B | -9.42M | -22.87M | 48.31M |
Balance Sheet | ||||||
| Total Assets | 3.30B | 3.35B | 3.44B | 4.55B | 4.55B | 992.93M |
| Cash, Cash Equivalents and Short-Term Investments | 172.00M | 185.50M | 129.00M | 170.94M | 245.57M | 381.05M |
| Total Debt | 774.20M | 793.70M | 912.61M | 906.24M | 897.53M | 0 |
| Total Liabilities | 1.22B | 1.25B | 1.37B | 1.40B | 1.42B | 105.56M |
| Stockholders Equity | 2.09B | 2.09B | 2.07B | 3.14B | 3.13B | 887.37M |
Cash Flow | ||||||
| Free Cash Flow | 49.75M | 31.90M | -46.35M | -76.16M | -24.73M | 43.61M |
| Operating Cash Flow | 85.25M | 83.20M | 58.24M | 35.26M | 41.03M | 68.04M |
| Investing Cash Flow | -35.42M | 70.50M | -99.19M | -29.31M | 201.04M | -97.23M |
| Financing Cash Flow | -19.01M | -99.40M | -1.60M | 1.92M | -118.08M | 6.81M |
Neogen Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NEOG, the sentiment is Negative. The current price of 10.90 is below the 20-day moving average (MA) of 11.81, below the 50-day MA of 12.20, and above the 200-day MA of 10.52, indicating a neutral trend. The MACD of -0.28 indicates Positive momentum. The RSI at 36.73 is Neutral, neither overbought nor oversold. The STOCH value of 7.14 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for NEOG.
Neogen Risk Analysis
Neogen disclosed 42 risk factors in its most recent earnings report. Neogen reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
3 New RisksNeogen Peers Comparison
Overall Rating
BIO78Outperform
NEOG60Neutral
BRKR57Neutral
RPID50Neutral
PACB44Neutral
QTRX40Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 78Outperform | $9.73B | 9.41 | 14.07% | ― | 1.38% | ― | |
| 60Neutral | $2.38B | -43.11 | -2.68% | ― | -0.33% | 94.64% | |
| 57Neutral | $9.37B | -55.94 | -5.15% | 0.33% | 2.16% | -604.24% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 50Neutral | $36.96M | -0.67 | -254.31% | ― | 20.78% | -9.39% | |
| 44Neutral | $569.53M | -4.39 | 604.22% | ― | 4.41% | 74.75% | |
| 40Underperform | $135.79M | -1.21 | -42.99% | ― | 13.78% | -1.29% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| NEOG | Neogen | 10.90 | 5.49 | 101.48% | |
| BIO | Bio-Rad Laboratories | 358.19 | 54.58 | 17.98% | |
| BRKR | Bruker Corporation | 61.36 | 17.71 | 40.56% | |
| PACB | Pacific Biosciences | 1.82 | -0.06 | -3.19% | |
| QTRX | Quanterix | 2.86 | -3.05 | -51.61% | |
| RPID | Rapid Micro Biosystems, Inc. Class A | 0.74 | -3.32 | -81.87% |
Neogen Corporate Events
Neogen Shareholders Approve Governance, Incentive and Audit Matters
PositiveOn October 1, 2026, Neogen Corporation held its 2026 Annual Meeting of Shareholders, with 176,180,487 of 218,106,005 eligible shares represented. Shareholders elected directors Aashima Gupta, Raphael A. Rodriguez, and Catherine E. Woteki, Ph.D., and...
Neogen announces board changes following director resignation
NeutralNeogen Corporation, a company with a corporate governance structure that includes a Board of Directors, reported a change in its leadership at the board level. The company relies on its directors to provide strategic oversight and guidance to managem...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 07, 2026
